國立虎尾科技大學 |

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The Challenge of CMC Regulatory Compliance for Biopharmaceuticals / by John Geigert.
Author:	Geigert, John.
Description:	XXVIII, 426 p. 59 illus., 34 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Pharmacology. -
Online resource:	https://doi.org/10.1007/978-3-030-13754-0
ISBN:	9783030137540

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
Geigert, John.

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals [electronic resource] /by John Geigert. - 3rd ed. 2019. - XXVIII, 426 p. 59 illus., 34 illus. in color.online resource.

Complexity of Biologics CMC Regulation -- Biopharmaceutics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Biopharmaceutical Source Materials -- Manufacturing of Biopharmaceutical APIs -- Manufacturing of the Drug Product -- Complex Process-Related Impurity Profiles -- Product Characterization is a Journey -- Priceless Potency (Therapeutic Activity) -- Quality Attributes of a Biopharmaceutical -- Designing the Stability Program -- The Art of Setting Specifications -- Demonstrating Product Comparability After Process Changes -- Invaluable CMC-Focused Meetings with Regulatory Authorities.

This book since first published in 2004 has been a major resource providing insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

ISBN: 9783030137540

Standard No.: 10.1007/978-3-030-13754-0doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
LDR:03317nam a22003975i 4500 001 1006327
003 DE-He213
005 20200629134022.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030137540 $9 978-3-030-13754-0
024 7 $a 10.1007/978-3-030-13754-0 $2 doi
035 $a 978-3-030-13754-0
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
100 1 $a Geigert, John. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1076228
245 1 4 $a The Challenge of CMC Regulatory Compliance for Biopharmaceuticals $h [electronic resource] / $c by John Geigert.
250 $a 3rd ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a XXVIII, 426 p. 59 illus., 34 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Complexity of Biologics CMC Regulation -- Biopharmaceutics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Biopharmaceutical Source Materials -- Manufacturing of Biopharmaceutical APIs -- Manufacturing of the Drug Product -- Complex Process-Related Impurity Profiles -- Product Characterization is a Journey -- Priceless Potency (Therapeutic Activity) -- Quality Attributes of a Biopharmaceutical -- Designing the Stability Program -- The Art of Setting Specifications -- Demonstrating Product Comparability After Process Changes -- Invaluable CMC-Focused Meetings with Regulatory Authorities.
520 $a This book since first published in 2004 has been a major resource providing insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmacy. $3 582411
650 1 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030137533
776 0 8 $i Printed edition: $z 9783030137557
776 0 8 $i Printed edition: $z 9783030137564
856 4 0 $u https://doi.org/10.1007/978-3-030-13754-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)